

13 March 2026

Release of Shares from Escrow

Philadelphia PA and Phoenix AZ, 13 March 2026: Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”) announces, pursuant to ASX Listing Rule 3.10A, that 3,111,145 fully paid ordinary shares will be released from voluntary escrow on 20 March 2026.

Authorised for release by

Vince Ippolito

Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for *Sofdra*, its product for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications
Botanix Pharmaceuticals
P: +61 8 6285 0083
info@botanixpharma.com

Investor enquiries

Hannah Howlett
P: +61 4 5064 8064
investors@botanixpharma.com

Media enquiries

Haley Chartres
H^CK
P: +61 423 139 163
haley@hck.digital

For personal use only